Braconi D, et al. - Researchers evaluated the baseline serum levels of established biomarkers related to inflammation and oxidative stress in samples from alkaptonuria (AKU) subjects enrolled in SONIA1 (n=40) and SONIA2 (n=138) clinical trials (DevelopAKUre project). In alkaptonuria (AKU), the worsening of symptoms was paralleled by increased inflammation and oxidative stress, which could play a role in disease progression. In AKU, monitoring of Serum Amyloid A (SAA) could be suggested to evaluate inflammation. Results suggested that SAA, chitotriosidase activity and PTI could be proposed as disease activity markers in AKU.